News


All series


All News

Research has shown that patients with para-aortic lymph node metastasis, human papillomavirus-18, and those with certain histocompatibility genes in their cervical tumors also have a poor prognosis. Preclinical research suggests, however, that immune checkpoint blockade with radiation can enhance immune-mediated activity in patients who have up to stage IV disease.

A new retrospective exploratory analysis has found no association between treatment with sorafenib and the development of sarcopenia among patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer. However, this analysis, which was published recently in Thyroid, did find that sorafenib had a significant effect on muscle mass.

Cetuximab plus mFOLFOX6 with the addition of avelumab resulted in an overall response rate of 81% in patients with RAS/BRAF-wildtype metastatic colorectal cancer, according to results of the phase II AVETUX study that were presented during the 2020 Gastrointestinal Cancers Symposium. But despite promising tumor responses, the trial missed its primary progression-free survival end point.

Myriad Genetics, Inc, has submitted a supplementary premarket approval application to the FDA for the myChoice CDx test for use in predicting outcomes for women with frontline platinum-responsive advanced ovarian cancer who are treated with niraparib, a PARP inhibitor, according to a press release from Myriad Genetics, Inc., the manufacturer of the test.

In an interview with&nbsp;Targeted Oncology, Benjamin Besse, MD, PhD,&nbsp;<a>discussed&nbsp;</a>the research around the Tedopi vaccine and how it addresses an unmet medical need for the treatment of patients with non-small cell lung cancer who have failed immune checkpoint inhibitors. He also explained the use of genomic testing to aid the treatment of non-small cell lung cancer.

Dasatinib, a second-generation Abl-tyrosine kinase inhibitor, used concurrently with an intensive chemotherapy regimen yields superior outcomes compared with imatinib plus chemotherapy in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to the results from the first randomized phase III clinical trial comparing the 2 drugs in this patients&nbsp;<a>population</a>.

The FDA granted Priority Review to the Biologics License Application for belantamab mafodotin, an anti&ndash;B cell maturation antigen monoclonal antibody for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapies included an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, GlaxoSmithKline plc announced in a press release.<br /> &nbsp;

A new phase III trial has found that luspatercept reduced the severity of anemia in patients with transfusion-refractory, lower-risk myelodysplastic syndromes with ring sideroblasts. Results from the MEDALIST trial, which included data from 65 sites in 11 countries, were published recently in the New England Journal of Medicine.

The FDA has granted a Priority Review to the New Drug Application for olaparib as treatment for patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations, who have progressed following prior treatment with a new hormonal agent, AstraZeneca reported in a press release.

The Investigational New Drug Application for the novel EGFR tyrosine kinase inhibitor BBT-176 was cleared by the FDA for treatment of&nbsp;EGFR C797S&ndash;mutant non&ndash;small cell lung cancer, according to a press release from Bridge Biotherapeutics, Inc, developer of BBT-176.

Lenvatinib demonstrated a longer median overall survival compared with palliative therapy in patients with stage IVC anaplastic thyroid cancer, a rare disease for which the survival rate has not improved in roughly 20 years. The introduction of targeted therapy to the treatment landscape for anaplastic thyroid cancer has been challenging in the past because some patients do not have time to undergo therapy on a clinical trial because the process is time-consuming, and the procedure for study enrollment may exceed time to progression.

Ruxolitinib plus low-dose&nbsp;pegylated interferon-a2 improved peripheral blood cell counts, bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis, according to the 2-year, end-of-study results of the phase II COMBI study, which were recently published in Haematologica.

For patients with non&ndash;small cell lung cancer, having a body mass index &ge;30 at baseline could be independently associated with an improvement in overall survival with atezolizumab and could be considered a stratification factor in immune checkpoint inhibitor trials, according to a study published in JAMA Oncology.